Changeflow GovPing Pharma & Drug Safety Peptide-derived KDM5C targeting cancer therapeu...
Routine Notice Added Final

Peptide-derived KDM5C targeting cancer therapeutics patent grant

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent US12589160B2 to NUVOBIO CORPORATION covering peptide-derived therapeutics targeting KDM5C for cancer treatment. The patent, filed on March 12, 2020, contains 6 claims and names inventors Kyle Kevin Biggar, Hemanta Adhikary, and Matthew Jacob Hoekstra. This grant establishes exclusive intellectual property rights for the assignee in the United States.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO issued Patent US12589160B2 to NUVOBIO CORPORATION for peptide compositions that bind KDM5C for cancer treatment. The patent claims priority to Application No. 17438925, filed March 12, 2020, and includes 6 claims covering the peptide therapeutics and their use in treating cancer (CPC: A61P 35/00). The invention relates to therapeutic applications of KDM5C-targeting peptides.

Patent holders should review the granted claims to assess their competitive landscape and consider filing complementary patents in related jurisdictions. Competitors developing KDM5C-targeting cancer therapeutics should evaluate potential infringement risks and consider design-around strategies. The patent maintains coverage through its term based on the 2020 filing date.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Peptide-derived therapeutics targeting KDM5C for the treatment of cancer

Grant US12589160B2 Kind: B2 Mar 31, 2026

Assignee

NUVOBIO CORPORATION

Inventors

Kyle Kevin Biggar, Hemanta Adhikary, Matthew Jacob Hoekstra

Abstract

The present invention relates to treatment of cancer. In particular, the present invention relates to peptides that bind KDM5C for the treatment of cancer.

CPC Classifications

A61K 47/645 A61K 38/00 A61P 35/00 C07K 7/06 C07K 7/08 C07K 2319/10 C12N 9/0071 C12Y 114/11

Filing Date

2020-03-12

Application No.

17438925

Claims

6

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12589160B2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent Licensing Cancer Therapeutic Development Biopharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!